PE20090682A1 - Secuencias peptidicas y composiciones - Google Patents

Secuencias peptidicas y composiciones

Info

Publication number
PE20090682A1
PE20090682A1 PE2008001614A PE2008001614A PE20090682A1 PE 20090682 A1 PE20090682 A1 PE 20090682A1 PE 2008001614 A PE2008001614 A PE 2008001614A PE 2008001614 A PE2008001614 A PE 2008001614A PE 20090682 A1 PE20090682 A1 PE 20090682A1
Authority
PE
Peru
Prior art keywords
sequences
lymphocytes
polypeptidic
residues
salival
Prior art date
Application number
PE2008001614A
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of PE20090682A1 publication Critical patent/PE20090682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Abstract

SE REFIERE A UNA COMPOSICION POLIPEPTIDICA, CONSTRUCCION POLIPEPTIDICA Y UNA CONSTRUCCION DE ACIDO NUCLEICO QUE CONTIENE DE 2 A 12 POLIPEPTIDOS SELECCIONADOS DE i) LAS SECUENCIAS SEQ ID 1-6, 20, 28, 30-32, 35, ENTRE OTROS, O DE LAS SUBSECUENCIAS DE ESTAS SECUENCIAS QUE TIENEN 7 O MAS AMINOACIDOS; ii) LAS SECUENCIAS DEFINIDAS POR LOS RESIDUOS AMINOACIDOS DE LA PROTEINA SALIVAL DE UN ARTROPODO TALES COMO LOS RESIDUOS DE AMINOACIDOS 2-33, RESIDUOS 2-26, RESIDUOS 2-25, ENTRE OTROS, O DE LAS SUBSECUENCIAS DE ESTAS SECUENCIAS QUE TIENEN 7 O MAS AMINOACIDOS; O iii) LAS SECUENCIAS POLIPEPTIDICAS QUE TENGAN 85% O MAS DE HOMOLOGIA CON UNA O MAS DE LAS SECUENCIAS DE i) O ii). DONDE DICHOS POLIPEPTIDOS SON EPITOPOS DE LINFOCITOS T CITOTOXICOS, LINFOCITOS T COLABORADORES Y LINFOCITOS B, SIENDO INMUNOGENICOS CONTRA PROTEINAS SALIVALES DE ARTROPODOS HEMATOFAGOS TALES COMO MOSQUITOS, GARRAPATAS, ACAROS, PULGAS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES TRANSMITIDAS POR ARTROPODOS TALES COMO MALARIA, FILARIASIS, TRIPANOSOMIASIS, DENGUE
PE2008001614A 2007-09-13 2008-09-15 Secuencias peptidicas y composiciones PE20090682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0717864.3A GB0717864D0 (en) 2007-09-13 2007-09-13 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
PE20090682A1 true PE20090682A1 (es) 2009-06-22

Family

ID=38658898

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001614A PE20090682A1 (es) 2007-09-13 2008-09-15 Secuencias peptidicas y composiciones

Country Status (25)

Country Link
US (2) US8986703B2 (es)
EP (4) EP2567706A3 (es)
JP (3) JP2010539127A (es)
CN (1) CN101815526B (es)
AR (1) AR068428A1 (es)
AU (1) AU2008297213B2 (es)
BR (1) BRPI0816330A2 (es)
CA (1) CA2699467A1 (es)
CL (1) CL2008002727A1 (es)
CO (1) CO6270336A2 (es)
DK (1) DK2783694T3 (es)
ES (1) ES2670859T3 (es)
GB (1) GB0717864D0 (es)
HU (1) HUE038953T2 (es)
MX (1) MX2010002025A (es)
NO (1) NO2783694T3 (es)
PE (1) PE20090682A1 (es)
PL (1) PL2783694T3 (es)
PT (1) PT2783694T (es)
RU (1) RU2466737C2 (es)
SG (1) SG187401A1 (es)
TR (1) TR201807414T4 (es)
TW (1) TWI548646B (es)
WO (1) WO2009034041A2 (es)
ZA (1) ZA201000914B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789094B1 (en) * 2004-08-13 2014-12-10 MARSHALL, Barry J. Bacterial delivery system
WO2009041037A1 (ja) * 2007-09-26 2009-04-02 Japan As Represented By The President Of National Cardiovascular Center 体内に存在する病因物質の低下剤
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
FR2955393B1 (fr) * 2010-01-18 2015-12-11 Inst Rech Developpement Ird Methode pour evaluer l'efficacite de strategies de lutte anti-vectorielle dans le controle du paludisme et des arboviroses
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
WO2015002134A1 (ja) * 2013-07-02 2015-01-08 公益財団法人がん研究会 細胞性免疫誘導ワクチン
WO2015060235A1 (ja) 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
CN104356216B (zh) * 2014-10-09 2017-03-01 昆明医科大学 版纳绳蚋防御肽SibaDef及其基因和应用
WO2016126457A1 (en) * 2015-02-02 2016-08-11 Yale University Mosquito saliva protein malaria vaccine
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
JP6893765B2 (ja) * 2016-07-15 2021-06-23 森山　雅美 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤
CN107236028B (zh) * 2017-07-05 2020-12-04 贵州医科大学 白纹伊蚊唾液34K2重组蛋白在DENV2感染HaCaT细胞中的应用
US20220328193A1 (en) * 2019-08-13 2022-10-13 Tata Consultancy Services Limited System and method for assessing the risk of prediabetes
US20220290248A1 (en) * 2019-08-13 2022-09-15 Tata Consultancy Services Limited System and method for assessing the risk of colorectal cancer
KR102615021B1 (ko) * 2021-10-14 2023-12-20 주식회사 메디트 3차원 스캐너의 스캔 이미지 정렬 방법, 장치 및 명령을 기록한 기록매체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2447843T3 (es) * 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso

Also Published As

Publication number Publication date
SG187401A1 (en) 2013-02-28
PL2783694T3 (pl) 2018-10-31
CA2699467A1 (en) 2009-03-19
AU2008297213A1 (en) 2009-03-19
MX2010002025A (es) 2010-03-15
USRE47222E1 (en) 2019-02-05
JP5981883B2 (ja) 2016-08-31
GB0717864D0 (en) 2007-10-24
US8986703B2 (en) 2015-03-24
NO2783694T3 (es) 2018-07-28
TWI548646B (zh) 2016-09-11
JP2010539127A (ja) 2010-12-16
HUE038953T2 (hu) 2018-12-28
EP2783694A3 (en) 2015-01-07
TR201807414T4 (tr) 2018-06-21
CO6270336A2 (es) 2011-04-20
EP2567706A3 (en) 2013-06-12
JP6227018B2 (ja) 2017-11-08
CL2008002727A1 (es) 2009-03-06
ES2670859T3 (es) 2018-06-01
JP2016135767A (ja) 2016-07-28
RU2010114597A (ru) 2011-10-20
JP2013240330A (ja) 2013-12-05
ZA201000914B (en) 2011-04-28
TW200920398A (en) 2009-05-16
EP2407172A1 (en) 2012-01-18
EP2182972A2 (en) 2010-05-12
CN101815526A (zh) 2010-08-25
PT2783694T (pt) 2018-06-07
WO2009034041A3 (en) 2009-06-25
RU2466737C2 (ru) 2012-11-20
WO2009034041A2 (en) 2009-03-19
AR068428A1 (es) 2009-11-18
AU2008297213B2 (en) 2013-01-24
CN101815526B (zh) 2014-03-19
EP2783694B1 (en) 2018-02-28
DK2783694T3 (en) 2018-06-14
BRPI0816330A2 (pt) 2015-04-14
EP2567706A2 (en) 2013-03-13
US20100297187A1 (en) 2010-11-25
EP2783694A2 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
PE20090682A1 (es) Secuencias peptidicas y composiciones
CL2021002464A1 (es) Composición farmacéutica, que comprende la variante de hialuronidasa humana ph20 y fármaco, para inyección subcutánea.
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
AR065169A1 (es) Variantes de la proteina de fusion de actriib y usos de las mismas
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
AR069989A1 (es) Formulaciones de vwf recombinantes
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
AR072967A1 (es) Polipeptidos del factor de estimulacion de la colonia de granulocitos bovino (bg-csf) modificados y sus usos
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
PE20140160A1 (es) Polipeptidos de relaxina modificados y sus usos
AR065349A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
AR073237A1 (es) Proteinas de bacillus thuringiensis que son toxinas activas contra hemipteros y coleopteros
AR078374A1 (es) Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas

Legal Events

Date Code Title Description
FC Refusal